ASIS for GAMMAGARD in Primary Immunodeficiency
Phase 1
- Conditions
- Interventions
- Drug: Gadolinium For abdomenDrug: Efficacy of Gammagard subcutaneously at Week 12Drug: Adverse Reactions of Gammagard subcutaneously at Week 12Drug: Gadolinium For lower backDrug: Efficacy of Gammagard subcutaneously at Week 24Drug: Adverse Reactions of Gammagard subcutaneously at Week 24Drug: Efficacy of Gammagard subcutaneously at Week 36Drug: Adverse Reactions of Gammagard subcutaneously at Week 36Drug: Efficacy of Gammagard subdermally at Week 36Drug: Adverse Reactions of Gammagard subdermally at Week 12Drug: Efficacy of Gammagard subdermally at Week 12Drug: Adverse Reactions of Gammagard subdermally at Week 24Drug: Efficacy of Gammagard subdermally at Week 24Drug: Adverse Reactions of Gammagard subdermally at Week 36
- First Posted Date
- 2014-04-25
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- ASIS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02123615
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
ASIS for Enbrel in Plaque Psoriasis
Phase 1
- Conditions
- Interventions
- Drug: Efficacy of Enbrel subcutaneously at Week 12Drug: PASI 75 n(%) subcutaneously at Week 12Drug: Adverse Reactions of Enbrel subcutaneouslyDrug: GadoliniumDrug: PASI 75 n(%) subcutaneously at Week 24Drug: Efficacy of Enbrel subcutaneously at Week 24Drug: Adverse Reactions of Enbrel subdermally at Week 36Drug: Efficacy of Enbrel subcutaneously at Week 36Drug: PASI 75 n(%) subcutaneously at Week 36Drug: Efficacy of Enbrel subdermally at Week 12Drug: PASI 75 n(%) subdermally at Week 12Drug: Efficacy of Enbrel subdermally at Week 24Drug: PASI 75 n(%) subdermally at Week 24Drug: Efficacy of Enbrel subdermally at Week 36Drug: PASI 75 n(%) subdermally at Week 36
- First Posted Date
- 2014-04-11
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- ASIS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02112097
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
ASIS for Botox in Chronic Migraine
Phase 1
- Conditions
- Interventions
- Drug: GadoliniumDrug: Efficacy of Botox intramuscularly at Week 6Drug: Adverse Reactions of Botox intramuscularlyDrug: Efficacy of Botox intramuscularly at Week 12Drug: Adverse Reactions of Botox subdermallyDrug: Efficacy of Botox intramuscularly at Week 18Drug: Efficacy of Botox intramuscularly at Week 24,Drug: Efficacy of Botox intramuscularly at Week 30Drug: Efficacy of Botox subdermally at Week 6Drug: Efficacy of Botox subdermally at Week 12Drug: Efficacy of Botox subdermally at Week 18Drug: Efficacy of Botox subdermally at Week 24Drug: Efficacy of Botox subdermally at Week 30
- First Posted Date
- 2014-02-28
- Last Posted Date
- 2015-06-24
- Lead Sponsor
- ASIS Corporation
- Target Recruit Count
- 60
- Registration Number
- NCT02074163
- Locations
- 🇺🇸
Automatic Subdermal Injector System, Inc, Westminster, California, United States
© Copyright 2024. All Rights Reserved by MedPath